SPP1, on the other hand, is a biomarker of fibrosis in NASH (Glass et al., 2018), primary sclerosing cholangitis (De Muynck et al., 2023), and of interstitial lung disease progression in SSC (Gao et al., 2020). Here, SPP1 is linked to metabolic dysfunction-associated steatohepatitis.